How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/partial-central-diabetes-insipidus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Partial Central Diabetes Insipidus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Partial Central Diabetes Insipidus (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Partial Central Diabetes Insipidus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lysipressin	LYPRESSIN	Novartis	lypressin	Vasopressin receptor	1982-01-01
Ddavp	DESMOPRESSIN	Ferring Pharms Inc	Factor VIII Activator	Vasopressin V1b receptor	1978-01-01
L-Lysine	LYSINE	Advanced Accelerator Applications	lysine	Glutathione reductase, mitochondrial
Minirin	Minirin	Hormozgan University of Medical Sciences		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
Argipressin	Argipressin	Kristina Svennerholm		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Advanced Accelerator Applications · 1 drug in Partial Central Diabetes Insipidus
Ferring Pharms Inc · 1 drug in Partial Central Diabetes Insipidus
Hormozgan University of Medical Sciences · 1 drug in Partial Central Diabetes Insipidus
Kristina Svennerholm · 1 drug in Partial Central Diabetes Insipidus
Novartis · 1 drug in Partial Central Diabetes Insipidus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Partial Central Diabetes Insipidus:

Cite this brief

Drug Landscape (2026). Partial Central Diabetes Insipidus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/partial-central-diabetes-insipidus. Accessed 2026-06-10.

Partial Central Diabetes Insipidus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing